Literature DB >> 23359264

CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.

Alexandre Boissonnas1, Fabrice Licata, Lucie Poupel, Sébastien Jacquelin, Luc Fetler, Sophie Krumeich, Clotilde Théry, Sébastian Amigorena, Christophe Combadière.   

Abstract

Chemotherapy enhances the antitumor adaptive immune T cell response, but the immunosuppressive tumor environment often dominates, resulting in cancer relapse. Antigen-presenting cells such as tumor-associated macrophages (TAMs) and tumor dendritic cells (TuDCs) are the main protagonists of tumor-infiltrating lymphocyte (TIL) immunosuppression. TAMs have been widely investigated and are associated with poor prognosis, but the immunosuppressive activity of TuDCs is less well understood. We performed two-photon imaging of the tumor tissue to examine the spatiotemporal interactions between TILs and TuDCs after chemotherapy. In a strongly immunosuppressive murine tumor model, cyclophosphamide-mediated chemotherapy transiently enhanced the antitumor activity of adoptively transferred ovalbumin-specific CD8(+) T cell receptor transgenic T cells (OTI) but barely affected TuDC compartment within the tumor. Time lapse imaging of living tumor tissue showed that TuDCs are organized as a mesh with dynamic interconnections. Once infiltrated into the tumor parenchyma, OTI T cells make antigen-specific and long-lasting contacts with TuDCs. Extensive analysis of TIL infiltration on histologic section revealed that after chemotherapy the majority of OTI T cells interact with TuDCs and that infiltration is restricted to TuDC-rich areas. We propose that the TuDC network exerts antigen-dependent unproductive retention that trap T cells and limit their antitumor effectiveness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359264      PMCID: PMC3556941          DOI: 10.1593/neo.121572

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.

Authors:  Pedro Berraondo; Clémence Nouzé; Xavier Préville; Daniel Ladant; Claude Leclerc
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

4.  Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

Authors:  Mohamed L Salem; Amir A Al-Khami; Sabry A El-Naggar; C Marcela Díaz-Montero; Yian Chen; David J Cole
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

Review 5.  Trophic macrophages in development and disease.

Authors:  Jeffrey W Pollard
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 6.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Authors:  Paola Allavena; Antonio Sica; Graziella Solinas; Chiara Porta; Alberto Mantovani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-29       Impact factor: 6.312

Review 7.  Combined modality immunotherapy and chemotherapy: a new perspective.

Authors:  Rupal Ramakrishnan; Scott Antonia; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

8.  Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Authors:  Mohamed L Salem; C Marcela Díaz-Montero; Amir A Al-Khami; Sabry A El-Naggar; Osama Naga; Alberto J Montero; Ahmed Khafagy; David J Cole
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 9.  Macrophage polarization in tumour progression.

Authors:  Antonio Sica; Paola Larghi; Alessandra Mancino; Luca Rubino; Chiara Porta; Maria Grazia Totaro; Monica Rimoldi; Subhra Kumar Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 10.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

View more
  40 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Authors:  Miranda L Broz; Mikhail Binnewies; Bijan Boldajipour; Amanda E Nelson; Joshua L Pollack; David J Erle; Andrea Barczak; Michael D Rosenblum; Adil Daud; Diane L Barber; Sebastian Amigorena; Laura J Van't Veer; Anne I Sperling; Denise M Wolf; Matthew F Krummel
Journal:  Cancer Cell       Date:  2014-10-16       Impact factor: 31.743

Review 3.  The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Authors:  Miranda L Broz; Matthew F Krummel
Journal:  Cancer Immunol Res       Date:  2015-04       Impact factor: 11.151

4.  Intravital multiphoton imaging of cutaneous immune responses.

Authors:  Kenji Kabashima; Gyohei Egawa
Journal:  J Invest Dermatol       Date:  2014-06-26       Impact factor: 8.551

Review 5.  Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems.

Authors:  Dickson K Kirui; Mauro Ferrari
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 6.  T cell migration, search strategies and mechanisms.

Authors:  Matthew F Krummel; Frederic Bartumeus; Audrey Gérard
Journal:  Nat Rev Immunol       Date:  2016-02-08       Impact factor: 53.106

Review 7.  Tumor-infiltrating dendritic cells in cancer pathogenesis.

Authors:  Jo Marie Tran Janco; Purushottam Lamichhane; Lavakumar Karyampudi; Keith L Knutson
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

Review 8.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

9.  Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.

Authors:  Bijan Boldajipour; Amanda Nelson; Matthew F Krummel
Journal:  JCI Insight       Date:  2016-12-08

10.  Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.

Authors:  Samarth Hegde; Varintra E Krisnawan; Brett H Herzog; Chong Zuo; Marcus A Breden; Brett L Knolhoff; Graham D Hogg; Jack P Tang; John M Baer; Cedric Mpoy; Kyung Bae Lee; Katherine A Alexander; Buck E Rogers; Kenneth M Murphy; William G Hawkins; Ryan C Fields; Carl J DeSelm; Julie K Schwarz; David G DeNardo
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.